Promising use of metformin in treating neurological disorders:biomarker-guided therapies  

作　　者：Allison Loan Charvi Syal Margarita Lui Ling He Jing Wang 

机构地区：[1]Regenerative Medicine Program,Ottawa Hospital Research Institute,Ottawa,ON,Canada [2]Department of Biology,Faculty of Science,University of Ottawa,Ottawa,ON,Canada [3]Department of Pediatrics and Medicine,Johns Hopkins Medical School,Baltimore,MD,USA [4]Department of Cellular and Molecular Medicine,Faculty of Medicine,University of Ottawa,Ottawa,ON,Canada [5]University of Ottawa Brain and Mind Research Institute,Ottawa,ON,Canada

出　　处：《Neural Regeneration Research》2024年第5期1045-1055,共11页中国神经再生研究（英文版）

摘　　要：Neurological disorders are a diverse group of conditions that affect the nervous system and include neurodegenerative diseases(Alzheimer’s disease,multiple sclerosis,Parkinson’s disease,Huntington’s disease),cerebrovascular conditions(stroke),and neurodevelopmental disorders(autism spectrum disorder).Although they affect millions of individuals around the world,only a limited number of effective treatment options are available today.Since most neurological disorders express mitochondria-related metabolic perturbations,metformin,a biguanide type II antidiabetic drug,has attracted a lot of attention to be repurposed to treat neurological disorders by correcting their perturbed energy metabolism.However,controversial research emerges regarding the beneficial/detrimental effects of metformin on these neurological disorders.Given that most neurological disorders have complex etiology in their pathophysiology and are influenced by various risk factors such as aging,lifestyle,genetics,and environment,it is important to identify perturbed molecular functions that can be targeted by metformin in these neurological disorders.These molecules can then be used as biomarkers to stratify subpopulations of patients who show distinct molecular/pathological properties and can respond to metformin treatment,ultimately developing targeted therapy.In this review,we will discuss mitochondria-related metabolic perturbations and impaired molecular pathways in these neurological disorders and how these can be used as biomarkers to guide metformin-responsive treatment for the targeted therapy to treat neurological disorders.

关 键 词：Alzheimer’s disease Huntington’s disease METFORMIN mitochondrial perturbation multiple sclerosis neural degenerative diseases Parkinson’s disease stroke targeted therapy 

分 类 号：R741[医药卫生—神经病学与精神病学]